In COVID-19 clinical update #115, Dr. Griffin reviews cross-variant immunity without vaccination, EUA for boosters in 5-11 year olds, B.1.1.529 attack rate, scent dogs, Omicron and pets, Paxlovid, Veklury, Fluvoxamine, antigen positivity after isolation, inflammasome activation and severe disease, and…
In COVID-19 clinical update #104, Daniel Griffin reviews effectiveness of mRNA vaccines among children, number of children affected by disease, accuracy of rapid antigen tests, CDC guidance for prevention strategies, monoclonal antibody effectiveness, predicting progression to severe respiratory failure from…
In COVID-19 clinical update #97, Daniel Griffin covers immunity after infection recognized by CDC, outcomes before and after Omicron, infectious viral load in Delta vs Omicron, PCR vs rapid antigen tests, booster interval shortened to 5 months, risk factors for…
Roger Seheult, MD of MedCram examines monoclonal antibodies and how they interact with the omicron variant. See all Dr. Seheult’s videos at: https://www.medcram.com Clinical trial data for Paxlovid show that if taken within 3 days of symptom onset, hospitalizations and…
Roger Seheult, MD of MedCram discusses the new omicron COVID variant. View all Dr. Seheult’s videos at: https://www.medcram.com (This video is MedCram COVID 19 update 138 and was recorded on November 29, 2021) Roger Seheult, MD is the co-founder and…
Scientists believe the new Omicron COVID-19 variant, also known as B.1.1.529, has dozens of mutations, fueling concerns it could be more transmissible. The variant has an estimated 50 mutations – most on spike proteins, and many more mutations than the…
